BioCentury
ARTICLE | Company News

Argolyn neurology news

August 3, 2009 7:00 AM UTC

Argolyn filed for Chapter 7 bankruptcy after the company determined its lead candidate for pain was not potent enough to continue development. The company's preclinical pipeline of neurotensin deriva...